BRPI0406800B8 - "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso - Google Patents

"dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso

Info

Publication number
BRPI0406800B8
BRPI0406800B8 BRPI0406800A BRPI0406800A BRPI0406800B8 BR PI0406800 B8 BRPI0406800 B8 BR PI0406800B8 BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 B8 BRPI0406800 B8 BR PI0406800B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition containing
peptide
peptide dimer
tumor antigen
Prior art date
Application number
BRPI0406800A
Other languages
English (en)
Inventor
Samizo Fumio
Sugiyama Haruo
Takasu Hideo
Original Assignee
Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd
Dainippon Sumitomo Pharma Co
Dainippon Pharmaceutical Co Ltd
Sugiyama Haruo
Int Inst Cancer Immunology Inc
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharmaceuticals Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd, Dainippon Sumitomo Pharma Co, Dainippon Pharmaceutical Co Ltd, Sugiyama Haruo, Int Inst Cancer Immunology Inc, Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharmaceuticals Company Ltd filed Critical Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd
Publication of BRPI0406800A publication Critical patent/BRPI0406800A/pt
Publication of BRPI0406800A8 publication Critical patent/BRPI0406800A8/pt
Publication of BRPI0406800B1 publication Critical patent/BRPI0406800B1/pt
Publication of BRPI0406800B8 publication Critical patent/BRPI0406800B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

peptídio dimerizado, composição farmacêutica contendo o mesmo e seu uso a presente invenção refere-se a um novo peptídio antígeno de tumor e a vacina para câncer do mesmo, de modo específico um dímero de peptídio, no qual dois monômeros de peptídio que consistem em 7 a 30 aminoácidos que incluem, pelo menos um resíduo de cisteína e sendo capazes de produzir um peptídio antígeno de tumor estão ligados um com o outro através de uma ligação de dissulfeto.
BRPI0406800A 2003-01-15 2004-01-15 "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso BRPI0406800B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003007122 2003-01-15
JP2003-007122 2003-01-15
PCT/JP2004/000254 WO2004063217A1 (ja) 2003-01-15 2004-01-15 二量体化ペプチド

Publications (4)

Publication Number Publication Date
BRPI0406800A BRPI0406800A (pt) 2006-01-17
BRPI0406800A8 BRPI0406800A8 (pt) 2016-11-01
BRPI0406800B1 BRPI0406800B1 (pt) 2020-08-11
BRPI0406800B8 true BRPI0406800B8 (pt) 2021-05-25

Family

ID=32709100

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406800A BRPI0406800B8 (pt) 2003-01-15 2004-01-15 "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso

Country Status (13)

Country Link
US (2) US20060217297A1 (pt)
EP (2) EP1584627B1 (pt)
JP (2) JP4498274B2 (pt)
KR (2) KR101399678B1 (pt)
CN (2) CN1756763B (pt)
AT (1) ATE444969T1 (pt)
AU (1) AU2004204031B2 (pt)
BR (1) BRPI0406800B8 (pt)
CA (1) CA2513701C (pt)
DE (1) DE602004023476D1 (pt)
ES (1) ES2332590T3 (pt)
HK (2) HK1081975A1 (pt)
WO (1) WO2004063217A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178956C (zh) * 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
TWI318630B (en) * 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
CN1511040A (zh) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
EP1550453B1 (en) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
ES2378264T3 (es) 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
DE602005020121D1 (de) * 2004-03-31 2010-05-06 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
BRPI0607326B8 (pt) * 2005-02-04 2021-05-25 Survac Aps composição de vacina, uso da referida composição e kit em partes
CN101336249A (zh) 2005-11-30 2008-12-31 株式会社癌免疫研究所 新型肽化合物
JP5393144B2 (ja) 2006-02-22 2014-01-22 株式会社癌免疫研究所 Ｈｌａ−ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
SI1987063T1 (sl) * 2006-02-23 2010-02-26 Fibrex Medical Res & Dev Gmbh Peptidi in peptidni derivati, njihova priprava in tudi njihova uporaba za pripravo terapevtsko in/ali profilaktično aktivnega farmacevtskega sestavka
US8653038B2 (en) * 2006-12-28 2014-02-18 International Institute Of Cancer Immunology, Inc. HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the same
RU2680539C2 (ru) 2007-02-27 2019-02-22 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Способ активации хелперных т-клеток и композиция для применения в данном способе
NZ599755A (en) * 2007-08-30 2013-08-30 Curedm Group Holdings Llc Compositions and methods of using proislet peptides and analogs thereof
SG189287A1 (en) 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
EP2655402A1 (en) * 2010-12-23 2013-10-30 Intercell Austria AG Oprf/i agents and their use in hospitalized and other patients
KR101993431B1 (ko) 2011-01-06 2019-06-26 바이오노르 이뮤노 에이에스 단량체형 및 다량체형 면역원성 펩타이드
WO2012105224A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 ワクチン・アジュバント
WO2014007266A1 (ja) 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
TWI646970B (zh) 2012-12-17 2019-01-11 大塚製藥股份有限公司 活化輔助ｔ細胞的方法
CA2905588C (en) 2013-03-12 2018-11-06 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
JP6671956B2 (ja) * 2013-03-29 2020-03-25 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
RU2668560C2 (ru) * 2013-03-29 2018-10-02 Сумитомо Дайниппон Фарма Ко., Лтд. Конъюгированная вакцина на основе пептида антигена wt1
KR20160063349A (ko) 2013-10-17 2016-06-03 서울대학교산학협력단 알파나선형 세포 투과 펩타이드 다합체，이의 제조방법 및 그 용도
DK3199175T3 (da) * 2014-09-27 2022-06-13 Sumitomo Pharma Co Ltd Farmaceutisk sammensætning til injektion
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
JP6515182B2 (ja) * 2015-05-20 2019-05-15 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
IL256880B2 (en) * 2015-07-14 2024-03-01 Yeda Res & Dev Combining proteins for the diagnosis of schizophrenia
US20200368338A1 (en) * 2017-12-27 2020-11-26 Sumitomo Dainippon Pharma Co., Ltd. Conjugate of wt1-derived peptides and composition comprising the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2268705T3 (es) * 1995-06-01 2007-03-16 Kishimoto, Tadamitsu Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1).
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
CN1178956C (zh) * 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
CA2349442C (en) * 1998-09-30 2012-12-04 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
JPWO2002047474A1 (ja) 2000-12-13 2004-04-15 住友製薬株式会社 Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
EP1447091A4 (en) * 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
WO2003028758A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
AU2003242305A1 (en) * 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
ES2378264T3 (es) 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
DE602005020121D1 (de) 2004-03-31 2010-05-06 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide

Also Published As

Publication number Publication date
KR20050098863A (ko) 2005-10-12
CN101851275A (zh) 2010-10-06
DE602004023476D1 (de) 2009-11-19
HK1081975A1 (en) 2006-05-26
ATE444969T1 (de) 2009-10-15
US20060217297A1 (en) 2006-09-28
CA2513701A1 (en) 2004-07-29
EP2154145A2 (en) 2010-02-17
ES2332590T3 (es) 2010-02-09
WO2004063217A1 (ja) 2004-07-29
HK1141539A1 (en) 2010-11-12
BRPI0406800A8 (pt) 2016-11-01
AU2004204031A1 (en) 2004-07-29
KR101399678B1 (ko) 2014-05-27
JP2010047603A (ja) 2010-03-04
BRPI0406800B1 (pt) 2020-08-11
JP4498274B2 (ja) 2010-07-07
EP1584627B1 (en) 2009-10-07
BRPI0406800A (pt) 2006-01-17
JPWO2004063217A1 (ja) 2006-06-01
US20100292164A1 (en) 2010-11-18
US8242084B2 (en) 2012-08-14
CN1756763A (zh) 2006-04-05
AU2004204031B2 (en) 2010-03-04
EP1584627A4 (en) 2006-03-15
EP1584627A1 (en) 2005-10-12
CA2513701C (en) 2013-06-18
EP2154145A3 (en) 2010-05-19
JP4926231B2 (ja) 2012-05-09
KR20120054644A (ko) 2012-05-30
EP2154145B1 (en) 2013-04-24
CN1756763B (zh) 2010-05-26

Similar Documents

Publication Publication Date Title
BRPI0406800B8 (pt) "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
HK1157180A1 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
NO20031048L (no) "Pseudo"-nativ kjemisk ligering
DK1454138T3 (da) Immunocytokiner med moduleret selektivitet
CY1116506T1 (el) Αντισωματα εναντι masp-2
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
ATE529126T1 (de) Stabilisierte pharmazeutische peptid zusammensetzungen
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
BR0305074A (pt) Composições cosméticas com alta afinidade
ATE459374T1 (de) Polypeptide enthaltende zusammensetzungen
CY1109444T1 (el) Φαρμακευτικη συνθεση που περιεχει κυκλικα αναλογα σωματοστατινης
EA200501230A1 (ru) Жидкие составы фактор некроза опухоли - связывающих белков
DE60317565D1 (de) Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE464383T1 (de) Tumor antigen
DE60229883D1 (de) Biologisch aktive peptide
ATE470678T1 (de) Emitter-bindende peptide, die eine veränderung der spektralen emissionseigenschaften des emitters bewirken
ATE263247T1 (de) Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugate
CY1117092T1 (el) Μοτιβα της οικογενειας παγκρεατικων πολυπεπτιδιων, πολυπεπτιδια και μεθοδοι που τα περιλαμβανουν
CY1116637T1 (el) Πολυπεπτιδια συντηξης igf-1 και θεραπευτικες χρησεις αυτων
SE0203226D0 (sv) Immunoglobulin bindning site

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA (CHUGAI PHARMACEUT

B25A Requested transfer of rights approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)